Diapharm’s AMNOG monitor provides up-to-date analyses of all Federal Joint Committee (G-BA) decisions regarding early benefit assessments.
It is an invaluable tool for decision-makers and managers, particularly those active in the fields of market access, pricing and reimbursement. Learn from the experiences of other market participants! This monthly source of professional assistance is available in German language.
Monthly updates plus the latest qualitative and quantitative analyses of G-BA decisions on all dossiers and indications for early benefit assessment, in addition to the ensuing pricing agreements:
Learn about the latest decisions and trends early on and obtain valuable information (lessons learnt) that will help you compile your own value dossiers and plan your clinical trials!